Lexaria Achieves Primary Endpoint in GLP-1-H24-4 Study with Significant Safety Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 24 2025
0mins
Source: NASDAQ.COM
- Significant Study Results: Lexaria achieved the primary endpoint in the GLP-1-H24-4 study, with all four DehydraTECH test arms demonstrating good safety, as DHT-semaglutide showed a 47.9% reduction in adverse events compared to Rybelsus, laying a solid foundation for future clinical applications.
- Adverse Event Reduction: The DHT-semaglutide formulation exhibited a 54.9% reduction in gastrointestinal adverse events, highlighting its safety advantages, which may attract more pharmaceutical companies to consider its product development.
- Funding Support: Lexaria secured approximately $7.5 million through two transactions since August 31, providing a financial runway for prospective new development opportunities in 2026, thereby enhancing its viability in a competitive market.
- Future Plans: Lexaria intends to pursue follow-on clinical testing to explore the potential of a DehydraTECH + SNAC + semaglutide composition, aiming to further validate its application prospects in diabetes treatment.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on LEXX
Wall Street analysts forecast LEXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEXX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.764
Low
1.50
Averages
1.50
High
1.50
Current: 0.764
Low
1.50
Averages
1.50
High
1.50
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
- Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
- Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
- Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.
Continue Reading
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
Continue Reading